Bipolar androgen therapy (BAT): A patient's guide. Issue 7 (31st March 2022)

• Record Type: Journal Article
• Authors: Denmeade, Samuel; Antonarakis, Emmanuel S; Markowski, Mark C
• Is Part Of: Prostate. Volume 82:Issue 7(2022)
• Page Start: 753
• Page End: 762
• Publication Date: 2022-03-31
• Subjects: androgen deprivation -- antiandrogen -- bipolar androgen therapy -- castration resistant; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.24328
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract: Bipolar androgen therapy (BAT) is a new treatment concept for men whose prostate cancer has become resistant to standard hormone‐blocking therapy. Over the past decade, we have performed a series of clinical studies testing BAT in asymptomatic men with castration‐resistant prostate cancer. The key findings from these clinical studies are that BAT (a) can be safely administered to asymptomatic patients with metastatic castrate‐resistant prostate cancer; (b) does not produce symptomatic disease progression; (c) produces sustained prostate‐specific antigen and objective responses in 30%–40% of patients; and (d) can resensitize and prolong response to subsequent antiandrogen therapy. The concept of BAT has generated significant interest from men with prostate cancer, their families, and their physicians. Here we provide a "Patient's Guide" that answers questions about BAT in a form that is accessible to patients, their families, and physicians. Our goal is to provide information to help patients make the most informed decisions they can regarding their prostate cancer treatment.